pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,401 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1093Endpoints827BioPharma Dive318BioSpace255Fierce Biotech239onclive165raps90globenewswire health73
therapy area
allOncology6594Rare Disease1561Cardiology1334Immunology1194Hematology1120Vaccines1046Pulmonology
  • Eli Lilly's TuneLab AI platform reaches 100 members and integrates Chai's models
    Eli Lilly has built TuneLab, an AI initiative that gives biotech companies free access to a range of artificial‑intelligence tools to support drug discovery and development. The program recently a…
    Endpoints · 2mo agoPositive↗ source
  • Super-potent nitazene opioids linked to sharp rise in U.S. overdose deaths
    Synthetic opioids known as nitazenes, which can be up to forty times stronger than fentanyl, are increasingly being found mixed into other street drugs across the United States. The Centers for Di…
    STAT · 2mo agoNegative↗ source
← prev
page 56 of 97
next →
fda recalls56
fda medwatch50
fda press32
968
Psychiatry & CNS774
Ophthalmology462
Pain429
Endocrinology & Metabolism409
Infectious Disease386
Eli Lilly stops 340B discounts for dozens of hospitals that did not submit claims data
Eli Lilly has begun removing the federally mandated 340B price discounts for a few dozen hospitals that have not provided the required claims data. The company said the step follows a warning it is…
STAT · 2mo agoRegulatoryNegative↗ source
  • RA Capital, Forbion and Sanofi Ventures back Korean eye-drug startup
    RA Capital, Forbion and Sanofi Ventures are reported to be providing financing for a new eye-drug company that is developing its product in Korea. The investment follows a growing pattern where la…
    Endpoints · 2mo agoDealNeutral↗ source
  • Former Senators Urge Congress to Prioritize Global Health as Strategic Diplomacy
    The authors, former U.S. senators, argue that improving global health must become a top priority for the United States, especially in light of recent outbreaks such as hantavirus and Ebola, which l…
    STAT · 2mo agoPositive↗ source
  • Patrick Soon-Shiong's pancreatic cancer claims lag behind reality, STAT reports
    STAT's Adam Feuerstein notes a wide gap between the outcomes promised by Patrick Soon-Shiong's pancreatic cancer therapies and the results that have actually been delivered. The columnist highlight…
    STAT · 2mo agoNegative↗ source
  • AI's rising electricity and water demand poses a public health risk, authors warn
    Two public-health scholars argue that the expanding use of artificial intelligence is creating a hidden strain on essential services such as electricity and water. They note that the massive data c…
    STAT · 2mo agoNegative↗ source
  • STAT Health Tech examines whether wearables benefit cardiovascular patients
    Mario Aguilar writes in a STAT Health Tech newsletter that the issue of wearables for people with cardiovascular disease is under review. The piece notes that researchers have been studying whether…
    STAT · 2mo agoNeutral↗ source
  • Cambrian’s experimental longevity drug shown to mimic exercise effects
    Cambrian Therapeutics reported early data on a new compound aimed at extending healthy lifespan by reproducing some benefits of physical activity. The preclinical studies described in the newslett…
    STAT · 2mo agoNeutral↗ source
  • Innoviva revives Lyndra's long-acting oral drug platform
    Innoviva, a healthcare asset and royalties holding firm, announced it is bringing back Lyndra's long-acting oral drug delivery platform. The technology, which previously attracted more than $380 mi…
    Endpoints · 2mo agoPositive↗ source
  • Industry eyes revenue potential of next‑generation peptide drugs beyond GLP‑1
    The article notes that just a few years ago analysts were busy estimating the market size for GLP‑1 based weight‑loss medicines. Today the conversation has shifted toward the commercial possibilit…
    Endpoints · 2mo agoNeutral↗ source
  • Trump administration earmarks $700 million for mental health and addiction programs, experts say funds are existing grants
    The Trump administration announced a $700 million allocation for mental health and addiction initiatives. Health Secretary Robert F. Kennedy Jr. described the money as new investments, but behavio…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • STAT+: Senate Democrats demand HHS provide records on federal vaccine policy
    Senate Democrats open an inquiry into the Trump administration’s remaking of U.S. vaccine policy, demanding officials produce records by next week.
    STAT · 2mo ago↗ source
  • What’s next for GLP-1 weight loss drugs?
    What’s next for GLP-1 weight loss drugs? Alex Hogan explores on the new episode of STATus Report. Watch now.
    STAT · 2mo ago↗ source
  • Antifungal from F2G, Shionogi succeeds in Phase 3 study
    F2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug. The companies said their treatment called o…
    Endpoints · 2mo ago↗ source
  • Kardigan extends biotech’s streak of big IPOs with $400M haul
    Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.
    BioPharma Dive · 2mo ago↗ source
  • Kardigan raises $400M in IPO to back three clinical-stage cardio drugs
    More evidence has arrived that biotech IPOs are alive and well: A cardiology drug developer with three clinical-stage candidates just secured $400 million for its Nasdaq debut slated for Thursday.…
    Endpoints · 2mo ago↗ source
  • Biogen makes up to $1B deal for secretive anti-inflammatory biotech
    Biogen will pay as much as $1 billion — “predominantly” in milestone payments — to acquire a San Diego biotech that has disclosed little about its pipeline. The startup, RayThera, debuted last year…
    Endpoints · 2mo ago↗ source
  • RFK Jr. presents $700 million in mental health funding, but experts say grants aren’t new
    RFK Jr. presents funding intended to address mental illness and addiction, particularly among homeless people.
    STAT · 2mo ago↗ source
  • STAT+: DOJ’s swift win in OhioHealth case should have hospitals studying their contracts, experts say
    The speed of DOJ's proposed antitrust settlement with OhioHealth should put other hospitals on notice, experts say.
    STAT · 2mo ago↗ source
  • FDA gives rejected drugs another chance in post-Makary era
    Did you receive a complete response letter in the past year? Now may be the time for a resubmission. In the wake of FDA Commissioner Marty Makary's departure last month, the agency has already agre…
    Endpoints · 2mo ago↗ source
  • FTC, four state AGs sue transgender health group over care standards
    The FTC and four state attorneys general have sued the main professional organization for gender-affirming care clinicians.
    STAT · 2mo ago↗ source
  • NIH diversity programs doubled undergraduates’ odds of getting a Ph.D., 20-year study finds
    A new study found that two diversity-oriented programs supported by the NIH doubled the odds that an undergraduate would earn a Ph.D.
    STAT · 2mo ago↗ source
  • FDA warns telehealth companies over compounded GLP-1s
    The FDA has issued a new batch of warning letters to 25 telehealth companies, accusing them of making false and misleading claims in their marketing of compounded GLP-1 weight loss drugs. The lette…
    Endpoints · 2mo ago↗ source
  • Luigi Mangione will assert psychiatric defense in murder case in UnitedHealthcare CEO’s killing
    Luigi Mangione plans to assert a psychiatric defense at his state murder trial, claiming he was suffering from extreme emotional disturbance when he gunned down UnitedHealthcare CEO Brian Thompson.
    STAT · 2mo ago↗ source